ATNM
Actinium Pharmaceuticals, Inc.
There isn't enough reported data to score ATNM yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ATNM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
ATNM's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ATNM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.9x | $1.03 | -35% |
| Fair | 3.3x | $1.17 | -27% |
| Expensive | 4.2x | $1.46 | -8.1% |
| Current | 4.5x | $1.59 | — |
Historical ranges are pointers, not guarantees.
ATNM's PE is 4.5x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ATNM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ATNM has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ATNM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.35 | +$1.66 |
| Q1 2026 | -$0.76 | +$0.71 |
| Q4 2025 | -$1.09 | +$0.18 |
| Q3 2025 | -$1.10 | +$0.29 |
| Q2 2025 | -$1.31 | +$0.20 |
| Q1 2025 | -$1.47 | +$0.24 |
| Q4 2024 | -$1.27 | +$0.56 |
| Q3 2024 | -$1.39 | +$0.54 |
ATNM has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ATNM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $45K | -81% |
| Q2 2022 | $45K | -83% |
| Q1 2022 | $940K | +51% |
ATNM has the stronger quarterly revenue trend. Revenue is up 77,678% for ATNM versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 79% | N/A |
| Q3 2025 | -6324% | N/A |
| Q3 2022 | -21776% | -18999 points |
| Q2 2022 | -17444% | -15537 points |
| Q1 2022 | -549% | +314 points |
| Q4 2021 | -34991% | N/A |
| Q3 2021 | -2776% | N/A |
| Q2 2021 | -1908% | N/A |
ATNM has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ATNM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$5.8M | +$1.7M |
| Q3 2024 | -$12M | -$820K |
| Q2 2024 | -$8M | +$5.7M |
| Q1 2024 | -$7.4M | +$7.8M |
| Q4 2023 | -$7.5M | +$304K |
| Q3 2023 | -$11.2M | -$5.4M |
| Q2 2023 | -$13.7M | -150% |
| Q1 2023 | -$15.2M | -$9.4M |
ATNM has the stronger cash trend. Its trailing FCF is down 27% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ATNM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +169K shares |
| 1 year | +0.7% | +211K shares |
| 3 years | +20% | +5.2M shares |
| 5 years | +55% | +11.2M shares |
| Available history | +477% | +26M shares |
ATNM has 31M diluted shares, up 0.7% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ATNM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ATNM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -3.7x | Net Cash |
ATNM has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over ATNM on leverage, with a lower net debt burden relative to earnings.
ATNM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.9 | Neutral |
| Stochastic | 82.3 | Overbought |
ATNM's weekly RSI is 64 (neutral) and its Stochastic is 82 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ATNM PE vs Healthcare Sector
| Metric | ATNM | Sector median | Relative |
|---|---|---|---|
| PE | 4.5x | 26x | 82% below |
ATNM is trading at 4.5x earnings, a 82% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ATNM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.33 | 20% above |
| 20 week MA | $1.14 | 39% above |
| 50 week MA | $1.19 | 34% above |
| 100 week MA | $1.32 | 20% above |
| 200 week MA | $3.86 | 59% below |
ATNM has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ATNM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.57 | $11.1 | +68% |
| 2021 | $11.1 | $6.66 | -40% |
| 2022 | $6.66 | $10.0 | +51% |
| 2023 | $10.0 | $5.08 | -49% |
| 2024 | $5.08 | $1.20 | -76% |
| 2025 | $1.20 | $1.52 | +27% |
| 2026 YTD | $1.52 | $1.59 | +4.6% |
ATNM has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.